Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 2
1988 3
1989 1
1990 2
1991 1
1992 1
1994 1
1996 1
1997 1
1998 1
1999 3
2000 2
2001 3
2002 2
2003 1
2004 4
2005 4
2006 3
2007 9
2008 8
2009 6
2010 9
2011 7
2012 7
2013 10
2014 17
2015 16
2016 17
2017 2
2018 5
2019 11
2020 13
2021 12
2022 7
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, Ross KN, Perner F, Olsen SN, Pritchard T, McDermott L, Jones CD, Jing D, Braytee A, Chacon D, Earley E, McKeever BM, Claremon D, Gifford AJ, Lee HJ, Teicher BA, Pimanda JE, Beck D, Perry JA, Smith MA, McGeehan GM, Lock RB, Armstrong SA. Krivtsov AV, et al. Among authors: lock rb. Cancer Cell. 2019 Dec 9;36(6):660-673.e11. doi: 10.1016/j.ccell.2019.11.001. Cancer Cell. 2019. PMID: 31821784 Free PMC article.
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer.
Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, Barahona P, Wilkie EE, Sullivan P, Bowen-James R, Syed M, Martincorena I, Abascal F, Sherstyuk A, Bolanos NA, Baber J, Priestley P, Dolman MEM, Fleuren EDG, Gauthier ME, Mould EVA, Gayevskiy V, Gifford AJ, Grebert-Wade D, Strong PA, Manouvrier E, Warby M, Thomas DM, Kirk J, Tucker K, O'Brien T, Alvaro F, McCowage GB, Dalla-Pozza L, Gottardo NG, Tapp H, Wood P, Khaw SL, Hansford JR, Moore AS, Norris MD, Trahair TN, Lock RB, Tyrrell V, Haber M, Marshall GM, Ziegler DS, Ekert PG, Cowley MJ. Wong M, et al. Among authors: lock rb. Nat Med. 2020 Nov;26(11):1742-1753. doi: 10.1038/s41591-020-1072-4. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020650
Circulating Tumor DNA in Pediatric Cancer.
Doculara L, Trahair TN, Bayat N, Lock RB. Doculara L, et al. Among authors: lock rb. Front Mol Biosci. 2022 May 12;9:885597. doi: 10.3389/fmolb.2022.885597. eCollection 2022. Front Mol Biosci. 2022. PMID: 35647029 Free PMC article. Review.
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.
Mayoh C, Mao J, Xie J, Tax G, Chow SO, Cadiz R, Pazaky K, Barahona P, Ajuyah P, Trebilcock P, Malquori A, Gunther K, Avila A, Yun DY, Alfred S, Gopalakrishnan A, Kamili A, Wong M, Cowley MJ, Jessop S, Lau LMS, Trahair TN, Ziegler DS, Fletcher JI, Gifford AJ, Tsoli M, Marshall GM, Haber M, Tyrrell V, Failes TW, Arndt GM, Lock RB, Ekert PG, Dolman MEM. Mayoh C, et al. Among authors: lock rb. Cancer Res. 2023 Aug 15;83(16):2716-2732. doi: 10.1158/0008-5472.CAN-22-3702. Cancer Res. 2023. PMID: 37523146 Free PMC article.
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Moles E, Howard CB, Huda P, Karsa M, McCalmont H, Kimpton K, Duly A, Chen Y, Huang Y, Tursky ML, Ma D, Bustamante S, Pickford R, Connerty P, Omari S, Jolly CJ, Joshi S, Shen S, Pimanda JE, Dolnikov A, Cheung LC, Kotecha RS, Norris MD, Haber M, de Bock CE, Somers K, Lock RB, Thurecht KJ, Kavallaris M. Moles E, et al. Among authors: lock rb. Sci Transl Med. 2023 May 17;15(696):eabm1262. doi: 10.1126/scitranslmed.abm1262. Epub 2023 May 17. Sci Transl Med. 2023. PMID: 37196067
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.
Germon ZP, Sillar JR, Mannan A, Duchatel RJ, Staudt D, Murray HC, Findlay IJ, Jackson ER, McEwen HP, Douglas AM, McLachlan T, Schjenken JE, Skerrett-Byrne DA, Huang H, Melo-Braga MN, Plank MW, Alvaro F, Chamberlain J, De Iuliis G, Aitken RJ, Nixon B, Wei AH, Enjeti AK, Huang Y, Lock RB, Larsen MR, Lee H, Vaghjiani V, Cain JE, de Bock CE, Verrills NM, Dun MD. Germon ZP, et al. Among authors: lock rb. Sci Signal. 2023 Mar 28;16(778):eabp9586. doi: 10.1126/scisignal.abp9586. Epub 2023 Mar 28. Sci Signal. 2023. PMID: 36976863
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia.
Shah K, Nasimian A, Ahmed M, Al Ashiri L, Denison L, Sime W, Bendak K, Kolosenko I, Siino V, Levander F, Palm-Apergi C, Massoumi R, Lock RB, Kazi JU. Shah K, et al. Among authors: lock rb. Blood Cancer J. 2023 Sep 7;13(1):139. doi: 10.1038/s41408-023-00914-7. Blood Cancer J. 2023. PMID: 37679323 Free PMC article.
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.
Li J, Hlavka-Zhang J, Shrimp JH, Piper C, Dupéré-Richér D, Roth JS, Jing D, Casellas Román HL, Troche C, Swaroop A, Kulis M, Oyer JA, Will CM, Shen M, Riva A, Bennett RL, Ferrando AA, Hall MD, Lock RB, Licht JD. Li J, et al. Among authors: lock rb. Cancer Discov. 2022 Jan;12(1):186-203. doi: 10.1158/2159-8290.CD-20-1771. Epub 2021 Aug 20. Cancer Discov. 2022. PMID: 34417224
176 results